Cargando…

Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank

BACKGROUND: Frailty, a state of reduced physiological reserve, is common in people with chronic obstructive pulmonary disease (COPD). Frailty can occur at any age; however, the implications in younger people (eg, aged <65 years) with COPD are unclear. We assessed the prevalence of frailty in UK B...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanlon, Peter, Lewsey, James, Quint, Jennifer K, Jani, Bhautesh D, Nicholl, Barbara I, McAllister, David A, Mair, Frances S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255399/
https://www.ncbi.nlm.nih.gov/pubmed/35787523
http://dx.doi.org/10.1136/bmjresp-2022-001314
_version_ 1784740913795301376
author Hanlon, Peter
Lewsey, James
Quint, Jennifer K
Jani, Bhautesh D
Nicholl, Barbara I
McAllister, David A
Mair, Frances S
author_facet Hanlon, Peter
Lewsey, James
Quint, Jennifer K
Jani, Bhautesh D
Nicholl, Barbara I
McAllister, David A
Mair, Frances S
author_sort Hanlon, Peter
collection PubMed
description BACKGROUND: Frailty, a state of reduced physiological reserve, is common in people with chronic obstructive pulmonary disease (COPD). Frailty can occur at any age; however, the implications in younger people (eg, aged <65 years) with COPD are unclear. We assessed the prevalence of frailty in UK Biobank participants with COPD; explored relationships between frailty and forced expiratory volume in 1 second (FEV1) and quantified the association between frailty and adverse outcomes. METHODS: UK Biobank participants (n=3132, recruited 2006–2010) with COPD aged 40–70 years were analysed comparing two frailty measures (frailty phenotype and frailty index) at baseline. Relationship with FEV1 was assessed for each measure. Outcomes were mortality, major adverse cardiovascular event (MACE), all-cause hospitalisation, hospitalisation with COPD exacerbation and community COPD exacerbation over 8 years of follow-up. RESULTS: Frailty was common by both definitions (17% frail using frailty phenotype, 28% moderate and 4% severely frail using frailty index). The frailty phenotype, but not the frailty index, was associated with lower FEV1. Frailty phenotype (frail vs robust) was associated with mortality (HR 2.33; 95% CI 1.84 to 2.96), MACE (2.73; 1.66 to 4.49), hospitalisation (incidence rate ratio 3.39; 2.77 to 4.14) hospitalised exacerbation (5.19; 3.80 to 7.09) and community exacerbation (2.15; 1.81 to 2.54), as was frailty index (severe vs robust) (mortality (2.65; 95% CI 1.75 to 4.02), MACE (6.76; 2.68 to 17.04), hospitalisation (3.69; 2.52 to 5.42), hospitalised exacerbation (4.26; 2.37 to 7.68) and community exacerbation (2.39; 1.74 to 3.28)). These relationships were similar before and after adjustment for FEV1. CONCLUSION: Frailty, regardless of age or measure, identifies people with COPD at risk of adverse clinical outcomes. Frailty assessment may aid risk stratification and guide-targeted intervention in COPD and should not be limited to people aged >65 years.
format Online
Article
Text
id pubmed-9255399
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-92553992022-07-20 Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank Hanlon, Peter Lewsey, James Quint, Jennifer K Jani, Bhautesh D Nicholl, Barbara I McAllister, David A Mair, Frances S BMJ Open Respir Res Chronic Obstructive Pulmonary Disease BACKGROUND: Frailty, a state of reduced physiological reserve, is common in people with chronic obstructive pulmonary disease (COPD). Frailty can occur at any age; however, the implications in younger people (eg, aged <65 years) with COPD are unclear. We assessed the prevalence of frailty in UK Biobank participants with COPD; explored relationships between frailty and forced expiratory volume in 1 second (FEV1) and quantified the association between frailty and adverse outcomes. METHODS: UK Biobank participants (n=3132, recruited 2006–2010) with COPD aged 40–70 years were analysed comparing two frailty measures (frailty phenotype and frailty index) at baseline. Relationship with FEV1 was assessed for each measure. Outcomes were mortality, major adverse cardiovascular event (MACE), all-cause hospitalisation, hospitalisation with COPD exacerbation and community COPD exacerbation over 8 years of follow-up. RESULTS: Frailty was common by both definitions (17% frail using frailty phenotype, 28% moderate and 4% severely frail using frailty index). The frailty phenotype, but not the frailty index, was associated with lower FEV1. Frailty phenotype (frail vs robust) was associated with mortality (HR 2.33; 95% CI 1.84 to 2.96), MACE (2.73; 1.66 to 4.49), hospitalisation (incidence rate ratio 3.39; 2.77 to 4.14) hospitalised exacerbation (5.19; 3.80 to 7.09) and community exacerbation (2.15; 1.81 to 2.54), as was frailty index (severe vs robust) (mortality (2.65; 95% CI 1.75 to 4.02), MACE (6.76; 2.68 to 17.04), hospitalisation (3.69; 2.52 to 5.42), hospitalised exacerbation (4.26; 2.37 to 7.68) and community exacerbation (2.39; 1.74 to 3.28)). These relationships were similar before and after adjustment for FEV1. CONCLUSION: Frailty, regardless of age or measure, identifies people with COPD at risk of adverse clinical outcomes. Frailty assessment may aid risk stratification and guide-targeted intervention in COPD and should not be limited to people aged >65 years. BMJ Publishing Group 2022-07-04 /pmc/articles/PMC9255399/ /pubmed/35787523 http://dx.doi.org/10.1136/bmjresp-2022-001314 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Chronic Obstructive Pulmonary Disease
Hanlon, Peter
Lewsey, James
Quint, Jennifer K
Jani, Bhautesh D
Nicholl, Barbara I
McAllister, David A
Mair, Frances S
Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank
title Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank
title_full Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank
title_fullStr Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank
title_full_unstemmed Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank
title_short Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank
title_sort frailty in copd: an analysis of prevalence and clinical impact using uk biobank
topic Chronic Obstructive Pulmonary Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255399/
https://www.ncbi.nlm.nih.gov/pubmed/35787523
http://dx.doi.org/10.1136/bmjresp-2022-001314
work_keys_str_mv AT hanlonpeter frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank
AT lewseyjames frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank
AT quintjenniferk frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank
AT janibhauteshd frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank
AT nichollbarbarai frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank
AT mcallisterdavida frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank
AT mairfrancess frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank